Navigation Links
Surveyed physicians report that acute kidney injury (AKI) is difficult to manage
Date:11/4/2015

BURLINGTON, Mass., Nov. 4, 2015 /PRNewswire/ -- Decision Resources Group finds that according to 44 percent of surveyed nephrologists and 37 percent of surveyed critical care physicians, AKI is highly difficult to manage and over 50 percent of both physician groups believe AKI is moderately difficult to manage. Current treatment and prevention options are limited and focus on supportive care. In addition, AKI management has remained largely unchanged in recent years.

Other key findings from the report entitled TreatmentTrends: Acute Kidney Injury (US) 2015:

  • Causes of AKI: Across both physician groups, infection (sepsis) is the leading cause of AKI. Other common causes include severe heart disease as well as nephrotoxic medications such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, diuretics, nonsteroidal anti-inflammatory drugs and others.
  • Current AKI diagnosis: A combination of both serum creatinine and urine output is used to diagnose AKI by both surveyed nephrologists and critical care physicians and use of biomarkers for diagnosis is currently rare.
  • Key Treatment Approaches for AKI: According to surveyed physicians, fluid management, withdrawal of offending medications, intermittent hemodialysis, and bicarbonate are the most common treatment approaches for AKI.
  • Challenges in AKI Treatment: Over a third of surveyed nephrologists mention lack of new and specific treatments and challenges with existing therapeutic approaches most often as a key challenge in the management of AKI. Critical care physicians cite fluid management as their biggest challenge in the management of AKI.
  • Top needs in AKI: The top needs for AKI are considered to be improving treatment of established AKI, aiding its prevention and identifying improved markers for earlier diagnosis. Patients with AKI due to sepsis are considered the group for which there is the highest need for new agents to prevent and treat AKI.
  • Alkaline phosphatase, CMX-2043, THR-184, Bendavia: Surveyed physicians reported moderate interest after reviewing the product profiles in clinical development for AM-Pharma's alkaline phosphatase, Ischemix's CMX-2043, Thrasos Therapeutics' THR-184 and Stealth BioTherapeutics' Bendavia. The report also discusses percentage of patients who would be likely candidates for these therapies after reviewing product profiles.

Comments from Decision Resources Group Business Insights Analyst Jihan Khan, Ph.D:

  • "AKI is a complex indication and extremely difficult to treat. The disease poses potentially catastrophic complications, including mortality. Although currently there are no products indicated to treat AKI, the pipeline is growing with many new agents in clinical development that may be able to address this complex patient population."

For more information on purchasing these reports, please email questions@teamdrg.com.

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value data, analytics and insights products and services to the healthcare industry, delivered by more than 900 employees across 14 global locations. DRG provides the pharmaceutical, biotech, medical device, financial services and payer industries with the tools, insights and advice they need to compete and thrive in an increasingly complex and value-based marketplace. DecisionResourcesGroup.com.

Media contact:

SHIFT Communications
Theresa Masnik
617.779.1871
dresourcesgroup@shiftcomm.com

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO


'/>"/>
SOURCE Decision Resources Group
Copyright©2015 PR Newswire.
All rights reserved


Related biology technology :

1. Surveyed Rheumatologists Report That Otezlas Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options
2. Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake
3. Surveyed U.S. Payers Are Significantly More Likely To Reimburse Biosimilars Developed By Multinational Manufacturers Compared With Those Developed By Regional Emerging Market Players
4. Surveyed Physicians Indicate that Xtandi is Prescribed to Nearly One Quarter of Metastatic Castrate-Resistant Prostate Cancer Patients Who Have Failed to Respond to Prior Docetaxel Treatment
5. At Three Months Post Launch, Two-Thirds of Surveyed U.S. Rheumatologists Believe that Initiations of Pfizers Xeljanz in the Rheumatoid Arthritis Treatment Algorithm Will Occur Following at Least Two Biologic Failures
6. Stem Cell Training Achieves 2015 Goal, Training 402 Physicians in 27 Cities Worldwide
7. WebMD and Medscape Surveys Explore Health Issues Facing Children, Parents and Physicians in Upcoming School Year
8. Supra Nimbus Announces a Suite of Tools that Enable Life Sciences Marketers to Better Reach Physicians with Brand Information
9. U.S. CDC committee recommends physicians make individual decisions on the use of meningococcal group B vaccines
10. New ASBM Survey Provides Physicians Views on Biosimilar Labeling
11. Elsevier Selected to Publish American College of Chest Physicians Flagship Journal CHEST
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2020)... ... 11, 2020 , ... Synagro Technologies, Inc. , the ... that the City of Fort Worth has partnered with Synagro of Texas-CDR (Synagro) ... of 2020, Synagro will assume operation of the city’s current biosolids management facility ...
(Date:2/5/2020)... FARMINGTON, Conn. (PRWEB) , ... February 04, 2020 ... ... that develops tools for characterizing microbiome populations down to the strain level, has ... Limited, will sell Shoreline Biome’s microbiome kits and other products to companies and ...
(Date:2/3/2020)... , ... February 03, 2020 , ... ... Financial Services Firm Travel, Law Firm Travel, Technology Industry Travel and Biotech/Healthcare Industry ... listed quarterly. Each Index illustrates the following statistics:, ...
(Date:1/28/2020)... ... January 28, 2020 , ... ... the exclusive distributor to food and beverage manufactures within North America. Both Lifecycle ... suppliers. This agreement will allow each company to pool their collective resources and ...
Breaking Biology Technology:
(Date:2/28/2020)... (PRWEB) , ... February 27, 2020 , ... ... broadcast 2Q/2020, will explore innovative treatment solutions for maladies, such as Inflammatory Bowel ... info. , This segment will focus on a novel platform developed by ...
(Date:2/28/2020)... ... February 28, 2020 , ... ... biologics orders. This includes all available stem cell and exosome biologics. , Regen ... tissue, Exosome Biologics, PRP kits, adipose kits, PDO thread lifts and more. ...
(Date:2/21/2020)... ... 2020 , ... Gateway Genomics , a leading developer of direct-to-consumer genetic ... annual Inc. 5000 list of fastest-growing private companies in the United States. ... the 17th fastest-growing private company in the state, and #1 in the Health sector. ...
Breaking Biology News(10 mins):